Randomized, Double-Blind, Placebo-controlled Phase 1 Study in Healthy Japanese Adult Subjects to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860
Phase of Trial: Phase I
Latest Information Update: 12 Oct 2016
At a glance
- Drugs JNJ 63871860 (Primary)
- Indications Escherichia coli infections; Urinary tract infections
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 03 Oct 2016 Status changed from recruiting to completed.
- 12 May 2016 Status changed from not yet recruiting to recruiting.
- 28 Apr 2016 New trial record